Skip to main content
  • Saved

made a Post

Analysis of KRAS mutations in circulating tumor DNA and colorectal cancer tissue

Analysis of KRAS mutations in circulating tumor DNA and colorectal cancer tissue

Source :

https://www.tandfonline.com/doi/abs/10.1080/10520295.2020.1810775

The mutation status of KRAS is important for anti-EGFR therapy in colorectal cancer (CRC) patients; however, detection of KRAS mutations in circulating tumor DNA (ctDNA) is problematic. We investigated tissue and plasma assays for KRAS mutations in CRC patients.